GLP-1 receptor agonist 1 (GLP-1 receptor agonist 1) is a GLP-1 receptor agonist extracted from patent WO2018056453A1, Compound 67
Free radicals are a natural, but undesirable, biproduct of cellular energy metabolism
Technically, Ozempic (semaglutide) was primarily and originally prescribed as a treatment for adults with type 2 diabetes
Niacinamide strengthens the skin barrier, reduces redness, and calms inflammation that can interfere with the repair process
Khavinson V, Goncharova N, Lapin B
That said, this is still emerging research, and more is needed to fully understand the long-term effects and potential of GLP-1 medications for different populations